Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraindividual comparison of methyl aminolevulinate versus BF-200 ALA photodynamic therapy for actinic keratosis
2015-002408-97Phase 4Completed
- Sponsor
- Dr. Carlos Serra
- Start
- Oct 2015
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methyl aminolevulinate and 5-aminolevulinic acid in actinic keratosis (AK) (2 arms), sponsored by Dr. Carlos Serra. Primary endpoint: Clinical response. Started Oct 2015; status: completed.
02
Drugs
methyl aminolevulinate5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2015-002408-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002408-97.